Literature DB >> 22013400

Hormesis pervasiveness and its potential implications for pharmaceutical research and development.

Kenneth I Maynard1.   

Abstract

This mini-review illustrates that hormesis is not only confined to the areas of biochemistry, radiation biology and toxicology, where it is traditionally known, but illustrates, by citing published scientific literature, that it is found across a wide range of biomedical science and clinical medicine such as neuroscience, cardiology and oncology. The use of techniques and technology, including high through-put screening, micro-dosing or phase 0 studies, pharmacometrics and adaptive trial design in the clinic, are proposed to illustrate how acknowledging the potential impact of hormesis throughout different stages of drug discovery and development, including hurdles related to efficacy and safety, could help the pharmaceutical industry address some of its major and frequently mentioned challenges.

Entities:  

Keywords:  dose response; drug development; drug discovery; hormesis; pharmaceutical industry; research and development

Year:  2011        PMID: 22013400      PMCID: PMC3186932          DOI: 10.2203/dose-response.11-026.Maynard

Source DB:  PubMed          Journal:  Dose Response        ISSN: 1559-3258            Impact factor:   2.658


  25 in total

1.  Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

Authors:  James Cross; Howard Lee; Agnes Westelinck; Julie Nelson; Charles Grudzinskas; Carl Peck
Journal:  Pharmacoepidemiol Drug Saf       Date:  2002-09       Impact factor: 2.890

Review 2.  The utility of microdosing over the past 5 years.

Authors:  Graham Lappin; R Colin Garner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-12       Impact factor: 4.481

3.  The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat.

Authors:  G P Schielke; N C Kupina; P A Boxer; C F Bigge; D F Welty; C Iadecola
Journal:  Stroke       Date:  1999-07       Impact factor: 7.914

4.  Cerebral hemorrhage due to heparin limits its neuroprotective effects: studies in a rabbit model of photothrombotic middle cerebral artery occlusion.

Authors:  B Q Zhao; Y Suzuki; K Kondo; K Kawano; Y Ikeda; K Umemura
Journal:  Brain Res       Date:  2001-05-25       Impact factor: 3.252

5.  Six-hour window of opportunity for calpain inhibition in focal cerebral ischemia in rats.

Authors:  C G Markgraf; N L Velayo; M P Johnson; D R McCarty; S Medhi; J R Koehl; P A Chmielewski; M D Linnik
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

6.  Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats.

Authors:  K Takahashi; J H Greenberg; P Jackson; K Maclin; J Zhang
Journal:  J Cereb Blood Flow Metab       Date:  1997-11       Impact factor: 6.200

7.  Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats.

Authors:  I A Ayoub; E J Lee; C S Ogilvy; M F Beal; K I Maynard
Journal:  Neurosci Lett       Date:  1999-01-04       Impact factor: 3.046

Review 8.  Hormesis and medicine.

Authors:  Edward J Calabrese
Journal:  Br J Clin Pharmacol       Date:  2008-06-28       Impact factor: 4.335

9.  Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.

Authors:  Fernando Doñate; Graham C Parry; Yuval Shaked; Harvey Hensley; Xiaojun Guan; Ivy Beck; Ziva Tel-Tsur; Marian L Plunkett; Mari Manuia; David E Shaw; Robert S Kerbel; Andrew P Mazar
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

10.  BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage.

Authors:  M J Leach; J H Swan; D Eisenthal; M Dopson; M Nobbs
Journal:  Stroke       Date:  1993-07       Impact factor: 7.914

View more
  4 in total

Review 1.  The Concept of Hormesis in Cancer Therapy - Is Less More?

Authors:  Andy Gaya; Charles A Akle; Satvinder Mudan; John Grange
Journal:  Cureus       Date:  2015-04-02

2.  Beyond new chemical entities: advancing drug development based on functional versatility of antibodies.

Authors:  Salvador Eugenio C Caoili
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 3.  Hormesis: Decoding Two Sides of the Same Coin.

Authors:  Dipita Bhakta-Guha; Thomas Efferth
Journal:  Pharmaceuticals (Basel)       Date:  2015-12-16

4.  The interplay between prior selection, mild intermittent exposure, and acute severe exposure in phenotypic and transcriptional response to hypoxia.

Authors:  Millicent N Ekwudo; Morad C Malek; Cora E Anderson; Lev Y Yampolsky
Journal:  Ecol Evol       Date:  2022-10-09       Impact factor: 3.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.